FOI release
ADR data GLP-1 medicines
Case reference FOI2026/00307
Received 18 March 2026
Published 8 May 2026
Request
I would like to receive information relating to Yellow Card adverse reaction reports received from Wales for GLP-1 medicines, in Excel format. Please provide a breakdown of adverse reaction reports relating to GLP-1 medicines received from Wales since 1st January 2024 per annual year by: * The sex of the patient affected * How many patients in each age group * The number of reports made by healthcare professionals, patients and carers * How many reports were sent directly to the MHRA and how many came via a pharmaceutical company * Seriousness - how many of the reported reactions were fatal, serious and non-serious * A breakdown of seriousness of cases by patient sex, age category and year report was received * A breakdown of seriousness by brand name (eg. Wegovy, Ozempic, Saxenda, Rybelsus and Mounjaro.) * Please also provide a breakdown of each seriousness category by system organ class * For these reported cases, please also provide a breakdown of whether the medication was prescribed by a doctor/other healthcare professional or bought at a pharmacy or online, or from an illegitimate supplier if this information is available. * Separately, please also specifically tell me how many reports of acute pancreatitis have been received from Wales relating to GLP-1 medicines and how many of these have been fatal, broken down by brand. * Also, separately, please also tell me how many reports have been received from Wales relating to falsified GLP-1 medicine for weight loss and any other breakdown you can provide for this data. Please send all of the data in Excel format. I look forward to hearing from you within 20 working days. If there are any issues with my request, please contact me to discuss as soon as possible.
Response
See attached
Documents
This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.